Correction

De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 (vol 28, pg 1700, 2017)

ANNALS OF ONCOLOGY (2019)

Journal

ANNALS OF ONCOLOGY

Volume 30, Issue 7, Pages 1181-1181

Publisher

OXFORD UNIV PRESS

DOI: 10.1093/annonc/mdy537

Keywords

-

Categories

Oncology

Funding

NIH [P30CA008748]

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Recommended

Article Oncology

Accelerating progress in early triple-negative breast cancer: A viewpoint on antibody-drug conjugates, back from St Gallen breast cancer conference 2021

Dario Trapani, Giuseppe Curigliano

Summary: Metastatic triple-negative breast cancer (mTNBC) is an aggressive disease with limited treatment options. Recent advancements in precision medicine have driven accelerated drug development in this field, offering more personalized treatments and improved outcomes. Antibody-drug conjugates (ADCs) have introduced a new paradigm in mTNBC by providing targeted treatment across multiple histology types.

BREAST (2022)

Add to Collection

Article Oncology

De-escalating axillary surgery in early-stage breast cancer

Eliza H. Hersh, Tari A. King

Summary: The role of axillary surgery in early-stage breast cancer has evolved over the years, with multiple clinical trials showing that axillary surgery may not be necessary in certain cases. Advances in imaging and genomic assays are likely to further reduce the need for axillary surgery, minimizing the morbidity of local therapy for women with breast cancer.

BREAST (2022)

Add to Collection

Review Oncology

Potential Impact of Preoperative Circulating Biomarkers on Individual Escalating/de-Escalating Strategies in Early Breast Cancer

Caterina Gianni, Michela Palleschi, Filippo Merloni, Sara Bleve, Chiara Casadei, Marianna Sirico, Giandomenico Di Menna, Samanta Sarti, Lorenzo Cecconetto, Marita Mariotti, Ugo De Giorgi

Summary: Advancements in molecular technologies have extended the potential role of circulating biomarkers in diagnosis, disease monitoring, and outcome prediction. Research is working towards personalized treatment in early breast cancer patients, and tools for intensification/de-intensification strategies are needed to guide clinicians' choices. Non-invasive circulating biomarkers, such as inflammatory circulating cells, circulating tumor cells (CTCs), cell-free DNA (cfDNA), and circulating tumor DNA (ctDNA), are improving treatment selection in early breast cancer.

CANCERS (2023)

Add to Collection

Review Obstetrics & Gynecology

Treatment of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: German Expert Opinions on the 17th International St. Gallen Consensus Conference

Michael Untch, Peter A. Fasching, Sara Y. Brucker, Wilfried Budach, Carsten Denkert, Renate Haidinger, Jens Huober, Christian Jackisch, Wolfgang Janni, Cornelia Kolberg-Liedtke, David Krug, Thorsten Kuehn, Sibylle Loibl, Diana Lueftner, Volkmar Mueller, Andreas Schneeweiss, Marc Thill, Nadia Harbeck, Christoph Thomssen

Summary: The 17th St. Gallen Consensus Conference on the Treatment of Patients with Early Breast Cancer focused on customizing local and systemic therapies for women with early breast cancer, emphasizing the challenge of individualized treatment. A German working group of leading breast cancer experts discussed the international conference results and compared them with the German guidelines to incorporate country-specific aspects. Both the German treatment recommendations of the AGO and the S3 guideline are evidence-based, but therapeutic decisions should always be based on a risk-benefit analysis for each specific situation and discussed with the patient.

GEBURTSHILFE UND FRAUENHEILKUNDE (2021)

Add to Collection

Article Oncology

Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021

H. J. Burstein, G. Curigliano, B. Thurlimann, W. P. Weber, P. Poortmans, M. M. Regan, H. J. Senn, E. P. Winer, M. Gnant

Summary: The 17th St Gallen International Breast Cancer Consensus Conference in 2021 was held virtually, with over 3300 participants discussing key issues related to early breast cancer diagnosis and treatment. The conference emphasized customized recommendations for breast cancer treatment, highlighting the importance of individualized clinical features in patient care.

ANNALS OF ONCOLOGY (2021)

Add to Collection

Article Multidisciplinary Sciences

Adequacy of early-stage breast cancer systemic adjuvant treatment to Saint Gallen-2013 statement: the MCC-Spain study

Ines Gomez-Acebo, Trinidad Dierssen-Sotos, Monica Mirones, Beatriz Perez-Gomez, Marcela Guevara, Pilar Amiano, Maria Sala, Antonio J. Molina, Jessica Alonso-Molero, Victor Moreno, Claudia Suarez-Calleja, Ana Molina-Barcelo, Juan Alguacil, Rafael Marcos-Gragera, Maria Fernandez-Ortiz, Oscar Sanz-Guadarrama, Gemma Castano-Vinyals, Leire Gil-Majuelo, Conchi Moreno-Iribas, Nuria Aragones, Manolis Kogevinas, Marina Pollan, Javier Llorca

Summary: The study aimed to identify the clinical factors associated with the implementation of the St Gallen-2013 recommendations. Patients who received treatment beyond the recommendations were more likely to have stage II tumors, while those who received less treatment than recommended tended to be older with more severe cancers.

SCIENTIFIC REPORTS (2021)

Add to Collection

Editorial Material Oncology

Escalating de-escalation in breast cancer treatment

Virgilio Sacchini, Larry Norton

Summary: Efforts have been made to reduce the intensity of treatment for breast cancer in order to balance treatment outcomes and patient quality of life. Neoadjuvant chemotherapy has gained popularity as a standard treatment for breast cancer. It is important to explore if the intensity of neoadjuvant approaches can be decreased while maintaining treatment outcomes. This editorial examines the available evidence and current trends in treatment de-escalation for women with breast cancer.

BREAST CANCER RESEARCH AND TREATMENT (2022)

Add to Collection

Review Oncology

De-Escalating the Management of In Situ and Invasive Breast Cancer

Fernando A. Angarita, Robert Brumer, Matthew Castelo, Nestor F. Esnaola, Stephen B. Edge, Kazuaki Takabe

Summary: De-escalation of breast cancer treatment can reduce morbidity and improve patients' quality of life. It is considered safe if the cancer outcomes are not affected compared to more aggressive treatments. This review provides an overview of de-escalation in the treatment of ductal carcinoma in situ (DCIS), local treatment of breast cancer, and surgery after neoadjuvant systemic therapy. Advancements in understanding the natural history and biology of breast cancer, imaging techniques, and adjuvant treatments have allowed for the reduction of treatment intensity. Identifying appropriate areas for de-escalation is crucial to minimize side effects while maintaining cancer outcomes. Less aggressive treatment modalities, or even no treatment, have been reconsidered if they achieve similar oncologic results as standard therapies. Careful consideration is needed to identify which patients benefit from de-escalation, as standard therapies still offer adequate cancer outcomes. This review highlights the importance of investigating de-escalation in breast cancer treatment, with future efforts aiming to clarify the role of different treatment modalities.

CANCERS (2022)

Add to Collection

Article Oncology

DECRESCENDO: de-escalating chemotherapy in HER2-positive, estrogen receptor-negative, node-negative early breast cancer

Veronique Debien, Virginie Adam, Elisabeth Coart, Elisa Agostinetto, Theodora Goulioti, Chiara Molinelli, Amal Arahmani, Gabriele Zoppoli, Martine Piccart

Summary: The DECRESCENDO trial is a prospective study evaluating the efficacy of neoadjuvant therapy with pertuzumab and trastuzumab, followed by taxane-based chemotherapy and adjuvant treatment, in patients with HER2-positive, hormone receptor-negative early breast cancer. The primary endpoint is the pathological complete response rate and 3-year recurrence-free survival rate. This trial offers the option of adjuvant treatment administration outside the hospital for some patients.

FUTURE ONCOLOGY (2023)

Add to Collection

Article Surgery

St Gallen 2019 guidelines understage the axilla in lobular breast cancer: a population-based study

U. Narbe, P-O Bendahl, M. Ferno, C. Ingvar, L. Dihge, L. Ryden

Summary: The study found that patients with ILC were more likely to have luminal A-like breast cancer and a higher nodal metastatic burden. The proportion of patients with at least four ALN metastases was higher in ILC compared to NST, highlighting the need to pay attention to the potential risk of nodal understaging and undertreatment when omitting cALND in patients with ILC.

BRITISH JOURNAL OF SURGERY (2021)

Add to Collection

Article Oncology

Practice-Changing Perspectives regarding Systemic Therapy in Early Breast Cancer: Opinions of German Experts regarding the 17th St. Gallen International Consensus Conference

Cornelia Kolberg-Liedtke, Diana Lueftner, Sara Y. Brucker, Wilfried Budach, Carsten Denkert, Peter A. Fasching, Renate Haidinger, Nadia Harbeck, Jens Huober, Christian Jackisch, Wolfgang Janni, David Krug, Thorsten Kuehn, Sibylle Loibl, Volkmar Mueller, Andreas Schneeweiss, Christoph Thomssen, Michael Untch, Marc Thill

Summary: This article introduces the general topic and voting results of the 17th St. Gallen International Consensus Conference, emphasizing the importance of considering the individual cancer situation in treatment decisions. It also highlights the significance of the German evidence-based treatment guidelines in interpreting the voting results, with a focus on systemic treatment.

BREAST CARE (2022)

Add to Collection

Review Medicine, General & Internal

The Lucerne Toolbox 2 to optimise axillary management for early breast cancer: a multidisciplinary expert consensus

Orit Kaidar-Person, Andre Pfob, Oreste Davide Gentilini, Bettina Borisch, Ana Bosch, Maria Joao Cardoso, Giuseppe Curigliano, Jana De Boniface, Carsten Denkert, Nik Hauser, Joerg Heil, Michael Knauer, Thorsten Kuehn, Han-Byoel Lee, Sibylle Loibl, Meinrad Mannhart, Icro Meattini, Giacomo Montagna, Katja Pinker, Fiorita Poulakaki, Isabel T. Rubio, Patrizia Sager, Petra Steyerova, Christoph Tausch, Trine Tramm, Marie-Jeanne Vrancken Peeters, Lynda Wyld, Jong Han Yu, Walter Paul Weber, Philip Poortmans, Peter Dubsky

Summary: Clinical axillary lymph node management in early breast cancer has evolved to involve the entire multidisciplinary team. The Lucerne Toolbox, a multidisciplinary consortium, addresses the challenges in clinical axillary lymph node management, proposing targeted imaging and standardized pathology as prerequisites to planning therapy, and the replacement of axillary lymph node dissection with sentinel lymph node biopsy in most scenarios. Positive patient outcomes should be driven by both low recurrence risks and low rates of lymphoedema.

ECLINICALMEDICINE (2023)

Add to Collection

Letter Medicine, General & Internal

Pembrolizumab in Early Triple-Negative Breast Cancer

Shuvadeep Ganguly, Ajay Gogia

Summary: In the KEYNOTE-522 trial, the addition of Pembrolizumab to neoadjuvant chemotherapy improved pathological complete response rate in early triple-negative breast cancer patients and also improved event-free survival. However, this improvement was predominantly observed in patients who did not achieve a pathological complete response.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Oncology

Late Recurrence Following Early Breast Cancer

Alexandra Thomas, Heather A. Parsons, Karen Lisa Smith

Summary: The Oncology Grand Rounds series aims to integrate research reports with clinical practice, helping readers better understand how to apply research findings to patient treatments.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Medicine, General & Internal

Breast-Conserving Surgery with or without Irradiation in Early Breast Cancer

Ian H. H. Kunkler, Linda J. J. Williams, Wilma J. L. Jack, David A. A. Cameron, J. Michael Dixon

Summary: This study suggests that omission of radiotherapy in older women with low-risk, hormone receptor-positive early breast cancer may increase the risk of local recurrence, but has no detrimental effect on distant recurrence and overall survival.

NEW ENGLAND JOURNAL OF MEDICINE (2023)

Add to Collection

Article Oncology

International development of a patient-centered core outcome set for assessing health-related quality of life in metastatic breast cancer patients

K. M. de Ligt, B. H. de Rooij, E. Hedayati, M. M. Karsten, V. R. Smaardijk, M. Velting, C. Saunders, L. Travado, F. Cardoso, E. Lopez, N. Carney, Y. Wengstrom, A. Ives, G. Velikova, M. D. L. Sousa Fialho, Y. Seidler, T. A. Stamm, L. B. Koppert, L. V. van de Poll-franse

Summary: For patients living with metastatic breast cancer (MBC), it is crucial to achieve the best possible health-related quality of life and maximize survival. However, there is currently no systematic way to determine if these goals are being achieved. A Core Outcome Set (COS) that allows standardized measurement of outcomes important to patients and promotes discussion of these outcomes during clinical encounters is urgently needed.

BREAST CANCER RESEARCH AND TREATMENT (2023)

Add to Collection

Article Oncology

Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial

Hope S. Rugo, Seock-Ah Im, Fatima Cardoso, Javier Cortes, Giuseppe Curigliano, Antonino Musolino, Mark D. Pegram, Thomas Bachelot, Gail S. Wright, Cristina Saura, Santiago Escriva-de-Romani, Michelino De Laurentiis, Gary N. Schwartz, Timothy J. Pluard, Francesco Ricci, William R. Gwin II, Christelle Levy, Ursa Brown-Glaberman, Jean-Marc Ferrero, Maaike de Boer, Sung-Bae Kim, Katarina Petrakova, Denise A. Yardley, Orit Freedman, Erik H. Jakobsen, Einav Nili Gal-Yam, Rinat Yerushalmi, Peter A. Fasching, Peter A. Kaufman, Emily J. Ashley, Raul Perez-Olle, Shengyan Hong, Minori Koshiji Rosales, William J. Gradishar

Summary: Clinical trials often report initial results based on the primary end point, while additional results from secondary analyses may not be available. In this study comparing margetuximab and trastuzumab in breast cancer patients, the final overall survival analysis did not show an advantage of margetuximab over trastuzumab. However, exploratory analysis suggested potential improvements in specific patient groups based on CD16A genotyping.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Add to Collection

Article Oncology

Associations of a Breast Cancer Polygenic Risk Score With Tumor Characteristics and Survival

Josephine M. N. L. Cardozo, Irene L. E. Andrulis, Stig E. Bojesen, Thilo M. Doerk, Diana M. A. Eccles, Peter A. J. Fasching, Maartje J. Hooning, Renske Keeman, Heli Nevanlinna, Emiel J. T. F. Rutgers, Douglas F. Easton, Per Hall, Paul D. P. J. Pharoah, Laura J. K. van't Veer, Marjanka K. Schmidt

Summary: A polygenic risk score (PRS) consisting of 313 common genetic variants (PRS313) is associated with risk of breast cancer and contralateral breast cancer. This study aimed to evaluate the association of the PRS313 with clinicopathologic characteristics of, and survival following, breast cancer. The results showed that PRS313 is associated with favorable tumor characteristics but not independently associated with prognosis. Rating: 8/10.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Add to Collection

Letter Surgery

Maximising the preservation of previously irradiated native mammary skin by skin-banking of the autologous flap: Outcome after 33 skin-sparing or nipple-sparing salvage mastectomies

Martine A. van Huizum, J. Joris Hage, Astrid N. Scholten, Emiel J. Rutgers

JOURNAL OF PLASTIC RECONSTRUCTIVE AND AESTHETIC SURGERY (2023)

Add to Collection

Article Oncology

Metformin, placebo, and endocrine therapy discontinuation among participants in a randomized double-blind trial of metformin vs placebo in hormone receptor-positive early-stage breast cancer (CCTG MA32)

Dawn L. L. Hershman, Bingshu E. E. Chen, Claire Sathe, Wendy R. R. Parulekar, Julie Lemieux, Jennifer A. A. Ligibel, Karen A. A. Gelmon, Timothy J. J. Whelan, Pamela J. J. Goodwin

Summary: This study analyzed the adherence and discontinuation rates of metformin and endocrine therapy (ET) among early-stage breast cancer patients. It found that adherence to metformin was low, while adherence to ET was good. Attention should be paid to the association between drug toxicity and adherence to improve patient medication adherence.

BREAST CANCER RESEARCH AND TREATMENT (2023)

Add to Collection

Article Oncology

Evolution of biological features of invasive lobular breast cancer: Comparison between primary tumour and metastases

Pamela Trillo, Jose Sandoval, Dario Trapani, Eleonora Nicolo, Paola Zagami, Federica Giugliano, Paolo Tarantino, Grazia Vivanet, Liliana Ascione, Alex Friedlaender, Angela Esposito, Carmen Criscitiello, Giuseppe Curigliano

Summary: The study retrospectively analyzed data of patients with recurrent invasive lobular carcinoma (ILC) and found discordance in the expression of ER, PgR, and HER2 between primary tumors and metastases. These findings suggest that phenotypic switch during metastasis may have implications for treatment decisions and prognosis in patients with ILC.

EUROPEAN JOURNAL OF CANCER (2023)

Add to Collection

Article Pharmacology & Pharmacy

Pharmacoeconomics of novel pharmacotherapies in triple-negative breast cancer

Luca Boscolo Bielo, Dario Trapani, Giuseppe Curigliano

Summary: Triple-negative breast cancer (TNBC), the most aggressive subtype of breast cancer with unfavorable outcomes, traditionally had limited systemic treatment options. However, novel drugs have been approved and are causing economic challenges due to their high prices.

EXPERT OPINION ON PHARMACOTHERAPY (2023)

Add to Collection

Review Oncology

Prolonging the life of people with metastatic breast cancer in routine clinical practice by adding palbociclib to an aromatase inhibitor from a real-world database analysis: a plain language summary

Hope S. Rugo, Adam Brufsky, Xianchen Liu, Benjamin Li, Lynn McRoy, Connie Chen, Rachel M. Layman, Massimo Cristofanilli, Mylin A. Torres, Giuseppe Curigliano, Richard S. Finn, Angela DeMichele

Summary: This is a summary of an article about a study called P-REALITY X, which found that patients with metastatic HR+/HER2- breast cancer treated with palbociclib plus an AI lived longer than those treated with an AI only in routine clinical practice. These results support the use of palbociclib plus an AI as the standard first-line treatment for this type of breast cancer.

FUTURE ONCOLOGY (2023)

Add to Collection

Letter Oncology

In Response to Morgan et al. and Li et al.

M. Goldberg, P. McGale, T. J. Whelan

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2023)

Add to Collection

Editorial Material Oncology

De-escalation in low-risk, HER2-positive breast cancer

Elena Geuna, Giuseppe Curigliano, Filippo Montemurro

LANCET ONCOLOGY (2023)

Add to Collection

Article Oncology

Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors

Emma Zattarin, Daniele Presti, Luigi Mariani, Caterina Sposetti, Rita Leporati, Alice Menichetti, Chiara Corti, Chiara Benvenuti, Giovanni Fuca, Riccardo Lobefaro, Francesca Ligorio, Leonardo Provenzano, Andrea Vingiani, Marta Del Vecchio, Gaia Griguolo, Marianna Sirico, Ottavia Bernocchi, Antonio Marra, Paola Zagami, Elisa Agostinetto, Flavia Jacobs, Pierluigi Di Mauro, Andrea Esposito, Carlo Alberto Giorgi, Luca Lalli, Laura Boldrini, Pier Paolo Berton Giacchetti, Ambra Carnevale Schianca, Valentina Guarneri, Rebecca Pedersini, Agnese Losurdo, Alberto Zambelli, Daniele Generali, Carmen Criscitiello, Giuseppe Curigliano, Giancarlo Pruneri, Filippo de Braud, Maria Vittoria Dieci, Claudio Vernieri

Summary: In 428 patients with HR+/HER2- advanced breast cancer, HER2-low status was found to be independently associated with worse progression-free survival (PFS) and overall survival (OS) compared to HER2-0 status. These findings suggest that HER2-low status could serve as a new prognostic biomarker in this clinical setting.

NPJ BREAST CANCER (2023)

Add to Collection

Article Oncology

Oncotype DX results increase concordance in adjuvant chemotherapy recommendations for early-stage breast cancer

Luca Licata, Giulia Viale, Mario Giuliano, Giuseppe Curigliano, Mariana Chavez-MacGregor, Julia Foldi, Oluchi Oke, Joseph Collins, Lucia Del Mastro, Fabio Puglisi, Filippo Montemurro, Claudio Vernieri, Lorenzo Gerratana, Sara Giordano, Alessia Rognone, Lorenzo Sica, Oreste Davide Gentilini, Stefano Cascinu, Lajos Pusztai, Antonio Giordano, Carmen Criscitiello, Giampaolo Bianchini

Summary: This study evaluates whether Oncotype DX improves confidence and agreement among oncologists in adjuvant chemotherapy recommendations for ER+/HER2- early-stage breast cancers. The study found that using Oncotype DX significantly reduces discordance and uncertainty among oncologists, and improves agreement in adjuvant chemotherapy recommendations for patients.

NPJ BREAST CANCER (2023)

Add to Collection

Article Oncology

PROCURE European consensus on breast cancer multigene signatures in early breast cancer management

Giuseppe Curigliano, Fatima Cardoso, Michael Gnant, Nadia Harbeck, Judy King, Anne-Vibeke Laenkholm, Frederique Penault-Llorca, Aleix Prat

Summary: Breast cancer multigene signatures (BCMS) have changed the management of early-stage breast cancer (eBC) by providing prognostic information and helping select patients for adjuvant chemotherapy. However, there is limited knowledge on the current usage and perceived utility of BCMS in clinical practice. A two-round Delphi survey involving 133 breast cancer experts from 11 European countries revealed that BCMS are widely used to assess risk of recurrence and select patients for adjuvant chemotherapy, but consensus is lacking regarding their utility in selecting specific chemotherapy types. There are also discrepancies between recommended usage and actual usage, with some profiles lacking supporting evidence. The study suggests the need for physician education initiatives to ensure proper use and interpretation of BCMS, ultimately improving management of eBC patients.

NPJ BREAST CANCER (2023)

Add to Collection

Article Cell Biology

Ki67 assessment protocol as an integral biomarker for avoiding radiotherapy in the LUMINA breast cancer trial

Torsten O. Nielsen, Samuel C. Y. Leung, Nazia Riaz, Anna M. Mulligan, Zuzana Kos, Anita Bane, Timothy J. Whelan

Summary: The LUMINA trial showed that in women aged 55 and above with low-risk luminal A breast cancer, very low local recurrence rate was observed when treated with breast-conserving surgery and endocrine therapy, supporting the safe omission of radiation. Ki67 is a practical, reproducible, and inexpensive biomarker that can identify low-risk luminal A breast cancers as potential candidates for radiation de-escalation.

HISTOPATHOLOGY (2023)

Add to Collection

Article Oncology

Quality of Life and Treatment-Related Side Effects in Patients With HR+/HER2-Advanced Breast Cancer: Findings From a Multicountry Survey

Fatima Cardoso, Julie Rihani, Victoria Harmer, Nadia Harbeck, Ana Casas, Hope S. Rugo, Peter A. Fasching, Adam Moore, Joanna de Courcy, Purnima Pathak, Sina Haftchenary, Dawn Aubel, Eva Schumacher-Wulf

Summary: This article examines the perspectives of healthcare professionals and patients on quality of life (QOL) and the impact of treatment-related side effects on QOL. The study found discrepancies between healthcare professionals and patients regarding the importance of QOL discussions and the impact of side effects on QOL.

ONCOLOGIST (2023)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.